NEW YORK--Nov. 2, 2000--Saliva Diagnostic Systems, Inc. (OTC: SALV, SALVE): The Company has received a Warning Letter from the US Food and Drug Administration ( FDA ). The Company had previously shipped HIV diagnostic products to exporters located in the United States (labeled for export only). The FDA determined t
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Nov. 2, 2000--ViroLogic, Inc. (NASDAQ: VLGC) today announced an agreement with Bristol-Myers Squibb Company (NYSE: BMY) to jointly educate physicians about HIV resistance testing and conduct important new drug resistance research. Under the agreement, Bristol-Myers Squibb a
BATON ROUGE, La. & FAR HILLS, N.J.--(BW HealthWire)--Oct. 5, 2000--Medisys Technologies, Inc. (OTCBB: SCEP) enthusiastically supports the HR 5178 Needlestick Safety Prevention Act introduced congress by Rep. Cass Ballenger (R-NC) and Rep. Mayor Owend (D-NY) to amend the Bloodborne Pathogen Standard administered by
SAN FRANCISCO & TEL AVIV, Israel--(BW HealthWire)--Oct. 5, 2000--A team of scientists at the University of California, San Francisco and Compugen Ltd. (Nasdaq:CGEN) has discovered a new molecule of the immune system -- a member of a family of proteins called chemokines which recruit the body s army of defensive imm
FARMINGDALE, N.Y.--(BUSINESS WIRE)--Oct. 2, 2000--Enzo Biochem, Inc. (NYSE:ENZ - news) reported today that new data on the first individual treated in the Phase 1 clinical trial of HGTV-43, the Company s HIV-1 gene medicine product, show that after nine-and-one-half-months Enzo engineered cells have successfully engraf
TORONTO--(BW HealthWire)--Sept. 18, 2000-- Several common HIV mutations do not always confer resistance to antiretroviral drugs as previously thought, according to data presented here at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). This important study highlights the complexity of
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Sept. 14, 2000-- ViroLogic, Inc. (NASDAQ: VLGC) today announced an agreement with Merck & Co. , Inc. (NYSE: MRK) to jointly develop and execute educational programs on the utility of HIV drug resistance testing for physicians across the nation. ViroLogic and Merck w
FORT MYERS, Fla.--(BW HealthWire)--Sept. 14, 2000-- ZipMed.com, Inc., a streaming media company serving online healthcare, and Reuters Health Information, Inc., the Internet s most trusted source of health news and information, today announced the launch of the Reuters Health Daily AudioCast, a daily streaming webcast
SAN DIEGO--(BW HealthWire)--Sept. 14, 2000--Maxim Pharmaceuticals (Nasdaq:MAXM)(SSE:MAXM) announced the 48-week results from its Phase II dose-ranging study of Maxamine(R) (histamine dihydrochloride) in combination with interferon-alpha (IFN-(alpha)) in the treatment of naive, chronically infected
FARMINGDALE, N.Y.--(BUSINESS WIRE)--Sept. 13, 2000-- The Farmingdale-based UNIVEC Corporation (Nasdaq:UNVC), the internationally recognized maker of auto-disable syringes, is heralding Preston Marx, Ph.D. and Ernest Drucker, Ph.D. on the release of their paper, The Injection Century: Consequences of Massive Unsterile I
BERKELEY, Calif.--(BW HealthWire)--Sept. 8, 2000--New drug discoveries are changing the way we live. From Viagra to protease-inhibitor cocktails, newly discovered drugs are expanding the quality and extending the length of our lives. But just how do these life-changing drugs go from concept to finished product? This fa
NEW YORK--(BW HealthWire)--Sept. 7, 2000--GayHealth.com(TM) today launched an innovative 60-day HIV-education initiative where activists, leaders and treatment specialists will share their expertise through the site s forums, surveys, chats and articles. GayHealth.com(TM) s campaign is in response to recent public heal
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 24, 2000-- Calypte Biomedical Corporation (Nasdaq: CALY) announced today that its HIV-1 antibody urine test has been approved by the State Drug Administration (SDA) of the People s Republic of China (PRC), making it the only urine-based HIV-1 test approved for distribution within
NUTLEY, N.J. and DURHAM, N.C.--(BW HealthWire)--Aug. 24, 2000-- Roche and Trimeris, Inc. (Nasdaq: TRMS) announced today that the Roche manufacturing facility in Boulder, Colorado (Roche Colorado) has been selected to manufacture commercial supplies of the investigational anti-HIV compound, T-20, the first of a new clas
FARMINGDALE, N.Y.--(BUSINESS WIRE)--Aug. 22, 2000--The Farmingdale-based UNIVEC Corporation (UNVC/NASDAQ), the internationally recognized maker of auto-disable syringes, today praised President Clinton for signing over the weekend the Global AIDS and Tuberculosis Relief Act of 2000. The legislation represents the lates
Calypte Biomedical Corporation (NASDAQ: CALY) announced today the expansion of its innovative mobile HIV-1 antibody urine testing program from South Africa to 41 countries in sub-Saharan Africa. The move is in response to the strong support expressed by medical professionals, AIDS activists and government officials in
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Aug. 8, 2000--OXO Chemie today completed enrollment in its Phase III clinical trial of WF10. The multicenter, randomized, double-blind, placebo-controlled study enrolled more than 240 late-stage HIV patients (no more than 50 CD4 cells/mm3) at 30 clinical sites in the
KIRKLAND, Wash.--(BW HealthWire)--July 21, 2000--Participants are being sought in 15 cities nationwide to take part in a clinical trial with a new cancer drug that can be self- administered as nose drops and has a favorable safety profile. A total of 200 patients with AIDS-related Kaposi s sarcoma are needed to partici
MIAMI--(BUSINESS WIRE)--July 12, 2000--Columbia Laboratories (AMEX:COB) today commented in response to a press release issued by UNAIDS that Advantage-S is a sustained and controlled release formulation containing 52.5 MG of N9 per dose initially designed to be used once daily. WHO/UNAIDS conducted and published a stud
DURBAN, South Africa--(BW HealthWire)--July 10, 2000-- Studies Using ViroLogic s Rapid, Accurate Phenotypic Resistance Test Contribute To Growing Body Of Scientific Knowledge on HIV Resistance Four studies of HIV drug resistance presented here at the XIII International AIDS Conference utilized PhenoSense HIV, the pheno
BEAVERTON, Ore.--(BW HealthWire)--July 10, 2000--Epitope, Inc. (NASDAQ NM: EPTO) has introduced the OraQuick(R) HIV-1/2 rapid HIV test to global AIDS/HIV policy leaders and decision makers attending the XIII International AIDS Conference currently underway in Durban, South Africa . Beginning at a reception held the
MIAMI--(BUSINESS WIRE)--June 12, 2000--Columbia Laboratories (AMEX: COB) today announced that its phase III multi-center, randomized, placebo controlled double blind study of Advantage-S in women at high risk of HIV infection failed to demonstrate that the product could prevent the transmission of the HIV virus. The re
FOSTER CITY, Calif.--(BW HealthWire)--June 12, 2000-- Gilead Sciences , Inc. (Nasdaq:GILD) announced today that it has begun enrolling patients in a second multinational Phase III clinical trial of tenofovir disoproxil fumarate 300 mg (tenofovir DF), its investigational agent for the treatment of human immunodeficiency
TORONTO--(BUSINESS WIRE)--June 2, 2000--HIV-VAC, Inc, (OTC/BB: HIVC) announced today that it is working towards initiating human trials in one or more African countries where HIV/AIDS has reached epidemic proportions. These new trials in Africa would compliment trials currently underway in Russia , and will also
FARMINGDALE, N.Y.--(BUSINESS WIRE)--June 2, 2000--Results Include Long-Term Survival in Humans of Engineered Cells and Development of CD4+ Cells Containing Anti-HIV-1 Antisense Genes Company to Propose Phase 2 Trial With AIDS Patients Enzo Biochem, Inc. (NYSE:ENZ) announced today preliminary results of a Phase 1 clinic
TORONTO--(BUSINESS WIRE)--June 1, 2000--HIV-VAC, Inc, (OTC/BB: HIVC) has announced that the Company has received funding to begin the final stages of laboratory testing for its HIV/AIDS vaccine that could prove to be both a preventative and therapeutic agent. The trials will be conducted at the Russia Aids
HOLLYWOOD, Fla.--(BW HealthWire)--May 22, 2000--Hep-C ALERT is now offering hepatitis C antibody blood tests to the public at a low cost of $25 each, anywhere in the U.S. at Quest Diagnostics Laboratory patient service sites (formerly SmithKline Beecham). One or more of every fifty people in the
CALGARY, Alberta--(BUSINESS WIRE)--May 18, 2000--SYNSORB Biotech Inc. ( SYNSORB ) (TSE:SYB, NASDAQ:SYBB), today announced that the U.S. Patent and Trademark Office (USPTO) has issued Patent 6,013,635 to the Corporation effective January 11, 2000. Issued in the United States , the patent establishes a firm intellectual
TORONTO--(BUSINESS WIRE)--May 15, 2000--Vasogen Inc. (TSE:VAS) (AMEX:MEW) today announced that University of Toronto researchers have identified interleukin-10 (IL-10), a cytokine produced by regulatory T cells, as a key factor in the anti-inflammatory mechanism of the Company s immune modulation therapies. IL-10 has b
SAN DIEGO--(BW HealthWire)--May 12, 2000--Vical Inc. (Nasdaq:VICL) announced today that an independent Drug Safety Review Board (DSRB) has recommended that current Phase II and Phase III registration trials targeting metastatic melanoma should progress as planned, based on a review of safety and preliminary efficacy da
Columbia Laboratories (AMEX:COB) today announced that patient enrollment had been completed and final patient visits initiated in the phase III multi-center, randomized, placebo controlled double blind study of Advantage-S(r) in women at high risk of HIV infection. Analysis of the data is expected by the end of June an
LAS VEGAS--(BW HealthWire)--May 3, 2000--In a series of discussions today, senior management of Steroidogenesis Inhibitors International Inc. (OTCBB:STGI) (TRADEGATE-SSJ-920435) has expressed its approval with the Clinton administration s serious concerns in combating the AIDS epidemic. In January, Vice President Al Go
SAN FRANCISCO--(BW HealthWire)--April 17, 2000--Researchers at the UCSF Center for AIDS Prevention Studies (CAPS) are looking for men and women living with HIV to participate in a new study aimed at improving health and well-being in the HIV community. Along with researchers at UCLA, Columbia University in New York, an
Every Hour, Two Americans Under the Age of 20 Become Infected With HIV. Cristina Saralegui Joins State to Announce Innovative Approach to AIDS Prevention *T WHAT: The California Department of Health Services (DHS) and Latina talk show host, Cristina Saralegui, will unveil the first AIDS prevention lowrider, which will
TORONTO--(BUSINESS WIRE)--April 7, 2000--HIV-VAC, Inc., (OTCBB:HIVC) announced today that the Company is supporting the Global AIDS Prevention Act of 2000. Sponsored by Senators Barbara Boxer (D-Calif.) and Gordon Smith (R-Ore.), this Congressional initiative will authorize $2 billion in funding which includes Sen. Joh
NEW YORK--(BUSINESS WIRE)--April 5, 2000--Earvin Magic Johnson will announce the partnership of the Magic Johnson Foundation and Secure the Future during a celebrity reception at the restaurant Reign in Beverly Hills on April 13. Secure the Future, a program sponsored by Bristol-Myers Squibb , is a five-year $100 mi
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--March 27, 2000--HIV disease management and clinical pathology are seeing a revolution with the introduction of therapeutic practices for managing patients health. In addition to viral load and CD4 cell monitoring, viral genotyping is emerging as a vital tool in improving the clin
OLYMPIA, Wash.--(BUSINESS WIRE)--March 22, 2000--Mortality rates for HIV/AIDS patients have been dropping steadily in Washington for the past several years, according to a Department of Health review. The result is a higher number of people living with HIV or AIDS enrolled in treatment and drug subsidy programs. Dr.
TORONTO--(BUSINESS WIRE)--March 14, 2000--HIV-VAC, Inc., (OTCBB:HIVC) today announced that it will be an active supporter of the recent initiative announced by President Clinton for the public and private sectors to concentrate efforts to bring HIV/AIDS vaccines to the developing world. On March 2, 2000, President Clin
NEW YORK--(BUSINESS WIRE)--March 13, 2000--Saliva Diagnostic Systems, Inc. (OTC BB:SALV) SDS will begin the process of obtaining FDA approval for its whole blood HIV1/2 rapid test using its patented Capillary Barrel System. SDS believes initial conversations with US government agencies have been extremely positive, and
NEW YORK--(BW HealthWire)--March 10, 2000--U.S. Food and Drug Administration Commissioner Jane E. Henney, MD, in an editorial posted first on medscape.com, www.medscape.com, has outlined a plan of attack increasing the FDA s power to combat online prescription drug sales that bypass the traditional safeguards created b
Amerimmune Pharmaceuticals Inc. (OTCBB:AMUN), a pharmaceutical research company that is developing Cytolin(R), a revolutionary treatment for patients suffering from human immunodeficiency virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS), today announced that it has formally begun the combined Phase I/II clini
OLYMPIA, Wash.--(BUSINESS WIRE)--March 3, 2000--In Washington state, 18 percent of reported AIDS cases are in African Americans -- a group that makes up only about 3 percent of the state s population. AIDS is the leading cause of death among African American men ages 25-49 in the United States , and is the second le
BEAVERTON, Ore.--(BW HealthWire)--Feb. 24, 2000--Epitope, Inc. (NASDAQ NM: EPTO) today announced a supply of the Company s OraSure(R) oral specimen collection device has been donated for use at The Whitman Walker Clinic, the primary source for HIV/AIDS services in the Washington, D.C. area. The OraSure devices will be
PALO ALTO, Calif.--(BW HealthWire)--Feb. 2, 2000--InterMune Pharmaceuticals today announced that it has initiated a Phase II clinical trial evaluating the safety, efficacy and dosing of Actimmune(R) (interferon gamma-1b) in the treatment of cryptococcal meningitis, a life-threatening fungal infection. The study will be
VANCOUVER, British Columbia--(BUSINESS WIRE)--Jan. 31, 2000-- ImmNetRes, Immune Network Research Ltd. (CDNX:IMM), announced today that a study published in the latest issue (volume 78, number 1) of The Journal of Immunology and Cell Biology reports that the company s anti-idiotypic antibody 1F7, selectively inhibits cy
SAN FRANCISCO--(BUSINESS WIRE)--Jan. 31, 2000--The Steering Committee for the Evaluation of Metabolic Complications of HAART (highly active antiretroviral therapy) will unveil its initial plans today at a symposium at the 7th Conference on Retroviruses and Opportunistic Infections in San Francisco to investigate the lo
DURHAM, N.C. and NUTLEY, N.J.--(BUSINESS WIRE)--Jan. 28, 2000-- A member of a new class of anti-HIV drugs, called fusion inhibitors is demonstrating its ability to suppress viral replication and remain well-tolerated in patients in an ongoing Phase II clinical trial. The investigational drug T-20, being developed throu
SAN DIEGO--(BW HealthWire)-- Jan. 27, 2000--Maxim Pharmaceuticals Inc. (AMEX:MMP) (SSE:MAXM) today announced that the United States Patent Office has allowed two key patents supporting the mechanism of action of the company s Maxamine(R) technology for the treatment of cancer and infectious diseases. These allowanc
TORONTO--(BUSINESS WIRE)--Jan. 27, 2000--HIV-VAC, Inc., (OTCBB:HIVC) today announced that Dr. Gordon Skinner, MD (Hons), DSc, FRCOG, FRCPath, the developer of the Skinner HIV-VAC AIDS vaccine, was interviewed by WebMd to discuss the vaccine s potential to end the worldwide AIDS epidemic. Dr. Skinner s interview with We
LAS VEGAS--(BW HealthWire)--Jan. 18, 2000.--(OTCBB:STGI) This project comes out in the wake of the terrible AIDS tragedy taking place in South Africa (see the recent article in Newsweek titled Ten million orphans------- ). STGI is firmly convinced that we can bring our own contribution, with our ANTICORT(TM)drug, in tr
MORRISTOWN, N.J.--(ENTERTAINMENT WIRE)--Jan. 18, 2000--A photographic exhibit portraying the struggles and triumphs of women living with HIV will be on display at the Morris Museum in Morristown, New Jersey. The incidence of HIV has nearly doubled within the last 10 years among women in the United States , making A
SAN DIEGO--(BW HealthWire)--Jan.7, 2000--Vical Inc. (Nasdaq:VICL) today announced the initiation by Merck & Co. Inc. (NYSE:MRK) of a Phase I clinical trial testing a naked DNA vaccine to prevent infection with the human immunodeficiency virus (HIV) that causes the acquired immunodeficiency syndrome (AIDS). Merc
TORONTO--(BUSINESS WIRE)--Jan. 3, 2000--HIV-VAC, Inc., (OTC BB:HIVC) announces that Dr. Gordon Skinner, MD (Hons), DSc, FRCOG, FRCPath, developer of the Skinner HIV-VAC AIDS vaccine will be featured in a one-hour, live, on-line audiocast on WebMD.com on Tuesday, January 4, 2000 at 3:00 PM EST. Go to http://my.webmd.com
TORONTO--(BUSINESS WIRE)--Jan. 3, 2000--HIV-VAC, Inc., (OTC BB:HIVC) announces that Dr. Gordon Skinner, MD (Hons), DSc, FRCOG, FRCPath, developer of the Skinner HIV-VAC AIDS vaccine will be featured in a one-hour, live, on-line audiocast on WebMD.com on Tuesday, January 4, 2000 at 3:00 PM EST. Go to http://my.webmd.com
This information is designed to support, not replace, the relationship that exists between you and your doctor.